Clinical Trials Logo

Programmed Cell Death 1 clinical trials

View clinical trials related to Programmed Cell Death 1.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05420922 Recruiting - Clinical trials for Hepatocellular Carcinoma

Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC

Start date: November 1, 2021
Phase:
Study type: Observational

China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously threatens the lives and health of the people. The investigators establish multi-center, retrospective research methods, collecting the data of HCC treatment with system treatment (ICIs and TKIs) plus or without local treatment in the last 3 years, comprehensive assessment of their efficacy and safety, explore whether the efficacy of system treatment combination local treatment showed better effect compared with system or local monotherapy. Our study will find a new way to improve the prognosis of HCC patients.

NCT ID: NCT04657237 Recruiting - Clinical trials for Programmed Cell Death 1

Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer

Start date: January 2017
Phase: N/A
Study type: Interventional

Surgery is first-line treatment for solid tumors. However, surgical trauma-induced physiologic stress has been demonstrated to facilitate metastasis and recurrence in different types of cancer. It has been reported that the PD-1/PD-L1 pathway could be activated by surgical stress. Hence, we instigate the effect of anesthetic technique on expression of PD1 and PD1 ligand.